Search Results

Showing results 51-61 of 93 for 'Cancer treatment'

  • Israeli-researchers-discovery-could-lead-to-new-type-of-cancer-treatment-thumb
  • steba-research-tn
    Steba Offers Prostate Cancer Patients a Better Approach

    It takes a village to bring a new treatment to market – and in the case of the prostate cancer therapy developed by Profs. Avigdor Scherz and Yoram Salomon, that village includes Steba Biotech, which said ""We looked at the technology for ten minutes and said, ‘We'll take it'."" Globes interviews the father and son behind the Israel-based pharmaceutical house.

  • group-of-t-cells-attack-tn
    T-cell Therapies for Cancer: From Outsider to Pharmaceutical Darling

    As Britain's Royal Pharmaceutical Society reports in its <em>Pharmaceutical Journal</em>, researchers working on T-cell therapies for cancer – such as Weizmann's Prof. Zelig Eshhar – were snubbed for years… until now. This thorough overview of the field's beginning – including in Prof. Eshhar's lab – and its future makes clear the importance of T cells.

  • US–Canadian-Fund-Looks-to-Israeli-Cancer-Researchers-for-Answers-thumb
  • safer-chemo-thanks-to-israeli-math-thumb
    Safer Chemo, Thanks to Israeli Math

    In a remarkable example of cross-disciplinary application, Weizmann Institute mathematicians and others developed a new model for evaluating infection risk for chemotherapy patients. The work could lead to a more individualized approach to cancer treatment.

  • cancer-drugs-while-you-sleep-tn
    Why Cancer Drugs May Work Better While You Sleep

    <em>Time</em> reports on the recent finding by Weizmann scientists that our bodies fight cancer better during the day, meaning that nighttime might be much better for administering cancer drugs. This ""happy accident"" is an example of how basic research can shed light on important issues.

  • the-transformation-tn
    The Transformation

    Writing in The New Yorker, Dr. Jerome Groopman examines whether controlling cancer is a more viable option than trying to destroy it. A new treatment for the often-fatal acute myelogenous leukemia (AML) aims to do just that by forcing immature cells to grow up, rather than turn into leukemia cells – a breakthrough that builds on the work of Weizmann's Prof. Leo Sachs.

  • triple-treatment-tn
    Triple Treatment Could Keep Lung Cancer from Coming Back

    ""Lung cancer is by far the leading cause of cancer death worldwide,"" states Israel21c in its coverage of new research from Weizmann's Prof. Yossi Yarden. Puzzled by some results in a trial that ""ran counter to everything we knew about the way tumors develop resistance,"" he discovered that a three-step treatment could prevent such resistance.

  • eshhar-zelig-tn
    Six Leading Scientists to Receive Prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology

    Prof. Zelig Eshhar, whose basic research led to the creation of cancer-killing T-cells, is one of six scientists to receive a 2016 Novartis Prize for Immunology. Announced and granted by the healthcare and pharma company, the prestigious prizes are ""awarded every three years for breakthrough contributions to the fields of basic and clinical immunology.""

  • alzheimers-patient-tn
    Cancer Drugs Could be Re-purposed to Fight Alzheimer’s Disease

    As The Telegraph reports, “a new generation of immunotherapy drugs for cancer may also help reverse Alzheimer's disease.” They’re referencing the work of Prof. Michal Schwartz, who investigates the immune system's role in neurological diseases. And since the cancer drugs are already in use, they may be able to quickly reach Alzheimer’s sufferers.